These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10075463)

  • 1. Effect of flutamide on survival in patients with pancreatic cancer. Results are impressive.
    Wigmore SJ; Fearon KC; Garden OJ
    BMJ; 1999 Jan; 318(7179):327; author reply 328. PubMed ID: 10075463
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of flutamide on survival in patients with pancreatic cancer. No recommendations can be made.
    Wasan HS
    BMJ; 1999 Jan; 318(7179):327-8. PubMed ID: 10075464
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of flutamide on survival in patients with pancreatic cancer. Study needs to be repeated on a much larger scale.
    Bramhall S; Buckels J
    BMJ; 1999 Jan; 318(7179):326-7; author reply 328. PubMed ID: 9924068
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Basic and clinical characteristics of flutamide].
    Suzuki K; Nakazato H; Kurokawa K; Yamanaka H
    Nihon Rinsho; 2000 Jul; 58 Suppl():211-5. PubMed ID: 11022716
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
    Pitts WR
    BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186
    [No Abstract]   [Full Text] [Related]  

  • 7. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

  • 9. Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
    Wilson KS; Ludgate CM; Wilson AG; Alexander AS
    Can J Urol; 2000 Oct; 7(5):1099-103. PubMed ID: 11114872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomised, double blind, placebo controlled trial.
    Greenway BA
    BMJ; 1998 Jun; 316(7149):1935-8. PubMed ID: 9641928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flutamide as a preoperative treatment in juvenile angiofibroma (JA) with intracranial invasion: report of 7 cases.
    Labra A; Chavolla-Magaña R; Lopez-Ugalde A; Alanis-Calderon J; Huerta-Delgado A
    Otolaryngol Head Neck Surg; 2004 Apr; 130(4):466-9. PubMed ID: 15100646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is flutamide effective in patients with bilateral orchiectomy?
    Rothman KJ; Johnson ES; Sugano DS
    Lancet; 1999 Apr; 353(9159):1184. PubMed ID: 10210003
    [No Abstract]   [Full Text] [Related]  

  • 13. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
    Taplin ME; Bubley GJ; Ko YJ; Small EJ; Upton M; Rajeshkumar B; Balk SP
    Cancer Res; 1999 Jun; 59(11):2511-5. PubMed ID: 10363963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer.
    Bolla M
    Eur Urol; 1999; 35 Suppl 1():23-5; discussion 26. PubMed ID: 10081699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.
    Negi SS; Agarwal A; Chaudhary A
    Invest New Drugs; 2006 May; 24(3):189-94. PubMed ID: 16133790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia in patients on combined androgen block therapy for prostate cancer.
    Qian LX; Hua LX; Wu HF; Sui YG; Cheng SG; Zhang W; Li J; Wang XR
    Asian J Androl; 2004 Dec; 6(4):383-4. PubMed ID: 15546035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the cost-effectiveness of flutamide in metastatic cancer.
    Hillner BE
    Cancer Treat Rev; 1996 Jan; 22 Suppl A():103-8. PubMed ID: 8625333
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.